Purpose: To evaluate serum markers of calcium metabolism in adult patients with epilepsy (PWE) treated with antiepileptic drugs (AEDs) and the effect of vitamin D supplementation on seizure frequency. 
Introduction
In the last few years the discovery of the systemic role of vitamin D has led to great interest in its functions in the modulation of physiological and pathological processes, as well as the prevention and treatment of many oncological [1] , cardiovascular [2] and neurological diseases, such as dementia [3] , Parkinson's disease [4] , multiple sclerosis [5] and schizophrenia [6] . Vitamin D is metabolized to its hormonal form 1,25-dihydroxyvitamin D (calcitriol, 1, 25 [OH]2D) in various organs such as the gut and kidney and, in this form, it enters the brain via the blood brain barrier to act directly on cells containing its nuclear receptor, the vitamin D receptor (VDR) [7] . The neuroprotective role and involvement of vitamin D in the function of the central nervous system is supported by the presence in the brain of the enzyme 25 [OH]D3-1a hydroxylase, which activates vitamin D, and by the expression of VDRs, especially in the hypothalamus and substantia nigra [8] .The enzyme 25 [OH]D3-1a-hydroxylase and nuclear VDRs are also present in the microglia, suggesting that vitamin D has both autocrine and paracrine effects on nervous system cells [9] .
The hormonal form of vitamin D works as neurosteroids do and affects multiple intracellular metabolic pathways [10] . In the field of epilepsy, the studies have mainly focused on the effects of antiepileptic drugs (AEDs) on vitamin D metabolism and bone status. Vitamin D deficiency has high prevalence among patients with epilepsy (PWE), and compelling evidence suggests that AEDs are major risk factor for bone disease in adult PWE [11] [12] [13] . Early reports have focused on AEDs inducing the hepatic cytochrome P450 enzyme system which, in turn, increases vitamin D metabolism. This mechanism would eventually lead to secondary hypocalcemia and hyperparathyroidism [14, 15] . Several other biological mechanisms would however make all types of AEDs potentially implicated in bone loss and disease [16] .
Very few studies have addressed the relationship between vitamin D deficiency and epilepsy itself. An anticonvulsant effect of vitamin D is supported by animal investigations [17, 18] , but confirmed on patients with drug-resistant epilepsy in only two clinical reports. However, the very small sample size of these studies does not allow one to draw any definite conclusion [19, 20] .
The aims of our study were to evaluate serum markers of calcium metabolism (25-hydroxy vitamin D, parathyroid hormone, calcium and phosphate) in a large sample of adult PWE treated with different AEDs and to evaluate the effect of oral vitamin D supplementation on seizure frequency in a subgroup of drug resistant patients.
Materials and methods

Study population and experimental design
A cross-sectional cohort study was conducted in our Epilepsy Center from 2014 to 2016. The study protocol was approved by the local Ethics Committee, and written informed consent was obtained from all participants. All procedures were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments.
We recruited epilepsy patients under chronic AED therapy (>6 months) and an age and sex-matched group of control subjects.
The exclusion criteria for patients and controls were: medical conditions affecting bone metabolism other than epilepsy, such as hepatic or renal disorders, hypothyroidism, obesity (body mass index >30 kg/m 2 ), malabsorption, history medications affecting calcium metabolism (e.g., vitamin A, anabolic steroids, bisphosphonates, glucocorticoids, thiazides, calcitonin, teriparatide) other than AEDs. One-hundred-sixty Caucasian adult PWE (age: 50.6 AE 19.3 years; 98 females) and forty-two age and sex matched controls (age: 52.7 AE 19.4 years; 27 females) were enrolled ( Table 1 ). All control subjects were Caucasian and were voluntarily enrolled among patients' relatives as they shared similar environmental conditions affecting vitamin D metabolism (e.g. diet, sunlight exposure).
On the basis of the neuroimaging data (CT scan and/or MRI), as well as the clinical and EEG features, 83 out of 160 patients were diagnosed as having focal epilepsy of unknown etiology, 63 as having structural focal epilepsy and the remaining 14 as having generalized idiopathic epilepsy. The structural focal epilepsy was due to: stroke/ischemic encephalopathy in 7 patients, nonparaneoplastic limbic encephalitis in 1, Temporal Lobe Epilepsy in 10 patients (4 patients with mesial sclerosis), post-traumatic encephalopathy in 12, cerebral hemorrhage in 3, perinatal encephalopathy in 8, Down Syndrome in 1, post-herpetic encephalopathy in 1, surgery for cerebral tumor in 10 patients (1 with oligodendroglioma, 1 with metastasis, 2 with astrocytoma, 6 with meningioma), suprasellar meningioma in 1, Alzheimer's Disease in 1, Progressive Myoclonic Epilepsy in 2, subependymal periventricular heterotopia in 1, cerebral cavernoma in 2, ArterioVenous Malformations in 2, cerebral vasculitis in 1 patient. The seizure frequency was collected through clinical diaries that were kept by the patients and their caregivers. During the 4 months before study start (baseline period), 63 patients (39.3%) were seizure free; the median seizure frequency in 4 months in the remaining 97 patients was 4 seizures (range: 1-240). The patients' response to AEDs on the basis of etiology classification of epilepsy was displayed in Table 2 . The type, number, dosage and administration schedule of drugs taken by the patients were recorded. Ninety-eight patients (61%) were on a single drug. The median number of AEDs used was 1 (range 1-5). The mean duration of antiepileptic treatment was 15.7 AE 16 years, ranging from 6 months to 63 years (Table 1) .
AEDs were classified according to their effect on the cytochrome P-450 system [21] . Enzyme-inducing AEDs [EIAEDs] were: Phenytoin, Phenobarbital, Primidone, Felbamate, Oxcarbazepine, Topiramate >200 mg/day [22] . Non-enzyme inducing AEDs (NEIAEDs) were: Valproate, Lamotrigine, Gabapentin, Tiagabine, Pregabalin, Levetiracetam, Topiramate 200 mg/day, Ethosuximide, Vigabatrin, Acetazolamide, Piracetam, Clobazam, Clonazepam, Zonisamide, Lacosamide. Depending on their AEDs, patients were classified as "only EIAEDs", "only NEIAEDs", "both EIAEDsNEIAEDs".
Thirty-nine (24.4%) patients were "only EIAEDs", 87 (54.4%) patients were "only NEIAEDs" and 34 (21.3%) patients were "both EIAEDs-NEIAEDs (Table 1) . 
Vitamin D supplementation
The investigation of the effect of vitamin D supplementation on seizure frequency was restricted to a subgroup of drug resistant epilepsy patients. In agreement with ILAE guidelines, drug resistant epilepsy was defined as failure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom [26] . After 6 months from the beginning of supplementation, all patients who received oral vitamin D were assessed to measure the serum levels of 25[OH]D and to evaluate changes in seizure frequency. Over this time period, the antiepileptic therapy was not modified.
Statistical analysis
Descriptive statistic is presented as mean AE standard deviation or median AE range, depending on data distribution. Data distribution was assessed by means of Kolmogorov-Smirnov tests.
Firstly, PWE and control subjects' measures were compared with Mann-Whitney U test or Chi-Square test, as appropriate.
Secondly, within the PWE group, the Mann-Whitney U test and Kruskal-Wallis tests were applied to assess serum 25 [OH]D concentration differences of patients in single therapy with respect of patients with polytherapy, as well as 'only EIAEDs', "only NEIAEDs" and "both EIAEDs-NEIAEDs" groups. Post-hoc comparisons were run whenever appropriate. Third, bivariate correlations between 25 [OH]D and iPTH and several parameters (age, therapy duration, seizure frequency) were performed with Spearman's correlation tests.
Lastly, the potential therapeutic effect of vitamin D on the changes in seizure frequency at 6 months [(seizure frequency POST -seizure frequency baseline)/seizure frequency baseline *100] was evaluated.
A p-value <0.05 was considered significant for all statistical analyses. Bonferroni correction for handling the apha inflation due to multiple comparisons was applied whenever appropriate. IBM SPSS Statistics version 20.0 (SPSS, Chicago, IL) was used for statistical analyses. (Fig. 2) . In particular, 25 [OH]D was significantly decreased in "both EIAEDs-NEIAEDs" patients compared to "only NEIAEDs" ("both EIAEDs-NEIAEDs" median = 10.3 ng/mL, range = 38.40; "only NEIAEDs" median = 15.90 ng/mL, range 44.90; Mann-Whitney U test = 2.653, p = .008), and a clear trend toward significance was found for the comparison between "only EIAEDs" and "only NEIAEDs" ("only EIAEDs" median = 12.6 ng/mL, range = 26.80; "only NEIAEDs" median = 15.90 ng/mL, range 44.90; Mann-Whitney U test = 1.918 p = .05). Also, serum calcium depended on the type of AEDs (Kruskal-Wallis test = 13.020, p = .001). In detail, serum calcium was significantly lower in "only EIAEDs" patients compared to "only NEIAEDs" ("only EIAEDs" median = 8.8 mg/dL, range = 8.23; "only NEIAEDs" median = 9.1 mg/dL, range 1.7; Mann-Whitney U test = 3.605, p < .001).
Results
Comparison PWE-Controls
Relationship between markers of calcium metabolism and clinical features of epileptic patients
As expected, we confirmed a strong inverse correlation between the serum levels of 25[OH]D and iPTH (Spearman's Rho = À0.279; p < .001). 25 [OH]D was inversely correlated with the duration of therapy (Spearman's Rho = À0.330; p < .001; Fig. 3,  left) , while the serum concentration of iPTH was positively correlated with the age of the patient (Spearman's Rho = 0.393; p < .001; Fig. 3, right) . 
Discussion
Our study confirmed previous reports regarding a higher prevalence of vitamin D deficiency in PWE with respect to controls, mainly due to antiepileptic therapy (number and type of AEDs). Moreover, oral vitamin D supplementation for three months in a subgroup of 48 drug resistant epileptic patients failed to significantly modify the seizure frequency.
Several studies have documented a high prevalence of vitamin D deficiency among PWE [11] [12] [13] 21] , mostly due to long-term therapy with enzyme-inducing AEDs. However, studies evaluating the vitamin D levels in outpatients with epilepsy have yielded conflicting results [28, 29] . Some of these reports were strongly impacted by the lack of direct comparison to the serum 25 [OH]D levels in control subjects. The prevalence of vitamin D deficiency is quite high in healthy subjects of industrialized countries. In our country, vitamin D deficiency reaches a prevalence of 30-50% in healthy adults and adolescents [30] [31] [32] . Our study confirmed these results, with an overall prevalence of vitamin D deficiency of 38.1% (31% had a vitamin D insufficiency and 7.1% showed a severe vitamin D deficiency).
Nonetheless, vitamin D was clearly decreased in PWE as compared to the already impaired controls (Fig. 1) . Antiepileptic therapies play a key role: patients taking multiple AEDs had lower levels of 25[OH]D than patients taking single therapy, and EIAEDs were more detrimental for the 25 [OH]D and calcium serum concentrations than NEIAEDs (Fig. 2) .
Several studies have implicated both EIAEDs and NEIAEDs for comorbid metabolic bone disease [12, 13, 33] . Moreover, numerous studies have shown that the serum 25 [OH]D levels were not significantly different between groups of subjects treated with either EIAEDs or NEIAEDs [14] . Additionally, conflicting results have been reported regarding the effect of AEDs on the bone mineral density [BMD] and fracture incidence [22] . However, the largest (high quality) study to-date [34] showed an increased hazard ratio of 9-22% for any fracture and 49-53% for hip fracture associated with the use of EIAEDs. Our study confirmed that patients taking EIAEDs are at greater risk for a lower serum concentration of 25 [OH]D and calcium. We also observed an inverse correlation between the serum level of 25[OH]D and duration of therapy (Fig. 3) . A recent study [35] found a strong correlation between the serum levels of 25[OH]D and duration of illness, duration of treatment with AEDs, BMD at the femoral neck and lumbar spine and markers of bone remodeling.
Our results are also consistent with evidence from clinical studies demonstrating that the risk of fractures was increased among patients receiving AED polytherapy compared with patients receiving monotherapy [36] as well as with the cumulative duration of AED exposure, with the strongest association found for more than 12 years of use [21] . Despite the strong negative correlation between the serum levels of 25[OH]D and iPTH in both groups, PWE and control subjects did not differ in serum increases of iPTH (20% in PWE and 22.7% in control subjects; Table 3 ). In fact, the only factor that affected the serum concentration of iPTH was the age of subjects (Fig. 3) , probably stronger than the effect of 25[OH]D serum changes. This relationship was previously elucidated by Adami et al. [37] , and related to the interaction of a number of age-dependant pathophysiologies, such as increasing growth factors, drug interactions or cytokine-induced interactions in chronic inflammatory diseases, or decreased vitamin D receptor quality and expression [37] . Thus, elderly people would become somewhat resistant to the effects of 25 [OH]D in a manner similar to the relative resistance to 1,25 dihydroxy-vitamin D previously reported in elderly adults [38] . in providing a complete and significant evaluation of vitamin D status, and, in particular, of calciferols acting at brain level. Thus, the lack of correlation between serum level of 25[OH]D and seizure frequency observed in our study could be related to this issue. In the same line, the treatment failure on seizure control could be due to a low cerebral concentration of the active metabolite, 1,25[OH]2D, resulting from a reduced BBB penetration and/or alterations of its synthesis and metabolism into the brain. Accordingly, it seems mandatory in the future studies to perform also an evaluation of serum 1,25[OH]2D, that is able to cross the BBB and to bind to VDR with higher affinity.
Our study tried to shed light on the need of vitamin D supplementation and its real impact on the seizure control. To the best of our knowledge, this is the largest clinical study investigating the possible vitamin D antiepileptic effect. The sample size is still limited and does not allow to draw definite conclusions, however our findings do not support an anticonvulsive effect of oral vitamin D supplementation, as previously suggested by some authors [18, 19] . Even if, for the same abovementioned reasons, there is not enough robust evidence that supports local (brain) low concentration of 1,25[OH]2D as the cause of the therapy failure, an alternative therapeutic approach could be the direct administration of calcitriol to test its potential antiseizure effect. However, this treatment could be harmful due to an excessive risk of hypercalcemia and hyperphosphatemia.
Conclusions
Epilepsy is one of the most common neurological disorders, and its treatment is life-long in nearly one-third of patients [43] . Our findings confirmed the high prevalence of alterations in calcium metabolism serum markers in PWE, mainly involving vitamin D deficiency and related to illness and therapy duration as well as the type of AED. Monitoring calcium metabolism and skeletal health in PWE becomes mandatory. Cholecalciferol supplementation is essential to prevent bone disorders and fractures, although on the basis of our results it does not seem to provide an antiepileptic effect. Further studies with larger sample size, randomized methods and the serum evaluation of 1,25[OH]2D in addition to 25 [OH]D will help to clarify this issue. Practical guidelines for the management of bone disease in PWE would be desirable. Evidence-based strategies regarding monitoring, prevention and treatment of bone diseases in patients on AED therapy are needed.
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